Publications by authors named "E Trabacchi"
We report the final analysis, with a 10-year follow-up, of the phase II study GIMEMA CML 0307 (NCT00481052), which enrolled 73 adult patients (median age 51 years; range, 18-83) with newly diagnosed chronic-phase chronic myeloid leukemia to investigate the efficacy and the toxicity of front-line treatment with nilotinib. The initial dose was 400 mg twice daily; the dose was reduced to 300 mg twice daily as soon as this dose was approved and registered. The 10-year overall survival and progression- free survival were 94.
View Article and Find Full Text PDFArticle Synopsis
- In chronic-phase chronic myeloid leukemia (CML), doctors use special medicines called tyrosine kinase inhibitors (TKIs) and aim for a treatment-free remission (TFR) after patients reach a stable deep molecular response (DMR).
- Some experts believe that every patient should have the chance to stop treatment if they reach DMR, while other guidelines focus more on keeping patients alive.
- A group of Italian experts talked about key things like predicting who can stop treatment, how to choose the right medicines for patients, how to check on the disease after stopping treatment, and the importance of therapy duration for successful remission.
Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival of CML patients has become very close to normal. The next, ambitious, step is to bring as many patients as possible into a condition of treatment-free remission (TFR).
View Article and Find Full Text PDFBackground: Although a wealth of efficacy and safety data is available for many tyrosine kinase inhibitors used in chronic myeloid leukemia (CML), there is a dearth of information on their impact on patients' health-related quality of life (HRQOL). The primary objective of this study was to evaluate HRQOL and fatigue outcomes in patients with CML receiving first-line therapy with nilotinib.
Methods: This was a multicenter, prospective study enrolling 130 patients with chronic-phase CML.